Display options
Cite
Mahlich J, Nishi M, Saito Y. Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. Clinicoecon Outcomes Res. 2015;7:267-72doi: 10.2147/CEOR.S85514.
Mahlich, J., Nishi, M., & Saito, Y. (2015). Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. ClinicoEconomics and outcomes research : CEOR, 7267-72. https://doi.org/10.2147/CEOR.S85514
Mahlich, Jörg, et al. "Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan." ClinicoEconomics and outcomes research : CEOR vol. 7 (2015): 267-72. doi: https://doi.org/10.2147/CEOR.S85514
Mahlich J, Nishi M, Saito Y. Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. Clinicoecon Outcomes Res. 2015 May 22;7:267-72. doi: 10.2147/CEOR.S85514. eCollection 2015. PMID: 26045674; PMCID: PMC4447166.
Copy Download .nbib Format: NLM
Share it on

Clinicoecon Outcomes Res. 2015 May 22;7:267-72. doi: 10.2147/CEOR.S85514. eCollection 2015.

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan.

ClinicoEconomics and outcomes research : CEOR

Jörg Mahlich, Masamichi Nishi, Yoshimichi Saito

Affiliations

  1. Health Economics, Janssen Pharmaceutical KK, Tokyo, Japan ; Düsseldorf Institute for Competition Economics, University of Düsseldorf, Düsseldorf, Germany.
  2. Pricing, Janssen Pharmaceutical KK, Tokyo, Japan.
  3. Health Economics, Janssen Pharmaceutical KK, Tokyo, Japan.

PMID: 26045674 PMCID: PMC4447166 DOI: 10.2147/CEOR.S85514

Abstract

BACKGROUND: The cost of schizophrenia in Japan is high and new long-acting injectable (LAI) antipsychotics might be able to reduce costs by causing a reduction of hospital stays. We aim to estimate budget effects of the introduction of a new 1-month LAI, paliperidone palmitate, in Japan.

METHODS: A budget impact analysis was conducted from a payer perspective. The model took direct costs of illness into account (ie, costs for inpatient and outpatient services, as well as drug costs). The robustness of the model was checked using a sensitivity analysis.

RESULTS: According to our calculations, direct total costs of schizophrenia reach 710,500 million yen a year (US$6 billion). These costs decrease to 691,000 million yen (US$5.9 billion) 3 years after the introduction of paliperidone palmitate.

CONCLUSION: From a payer point of view, the introduction of a new treatment for schizophrenia in Japan helps to save resources and is not associated with a higher financial burden.

Keywords: Japan; budget impact; long-acting injectables; paliperidone; schizophrenia

References

  1. Eur J Health Econ. 2010 Dec;11(6):585-94 - PubMed
  2. Am Health Drug Benefits. 2014 Jan;7(1):18-26 - PubMed
  3. BMC Psychiatry. 2010 Jan 07;10:2 - PubMed
  4. Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):181-94 - PubMed
  5. Clinicoecon Outcomes Res. 2011;3:9-14 - PubMed
  6. Neuropsychiatr Dis Treat. 2013;9:587-94 - PubMed
  7. J Med Econ. 2015 ;18(8):629-36 - PubMed
  8. Appl Health Econ Health Policy. 2013 Oct;11(5):509-21 - PubMed
  9. Neuropsychiatr Dis Treat. 2013;9:787-98 - PubMed
  10. Pharmacoeconomics. 2005;23 Suppl 1:49-61 - PubMed
  11. Schizophr Res. 2011 Apr;127(1-3):83-92 - PubMed
  12. Appl Health Econ Health Policy. 2008;6(1):41-53 - PubMed
  13. Eur Psychiatry. 2009 Jun;24(5):287-96 - PubMed
  14. Psychiatry Clin Neurosci. 2007 Feb;61(1):71-7 - PubMed
  15. Eur Psychiatry. 2014 Oct;29(8):479-89 - PubMed
  16. Schizophr Res. 2009 Feb;107(2-3):213-7 - PubMed
  17. Neuropsychopharmacology. 2010 Nov;35(12):2367-77 - PubMed
  18. Health Econ Policy Law. 2011 Jul;6(3):369-89 - PubMed
  19. Neuropsychiatr Dis Treat. 2015 Apr 01;11:935-40 - PubMed
  20. J Ment Health Policy Econ. 2007 Mar;10(1):23-41 - PubMed
  21. Clinicoecon Outcomes Res. 2013 Aug 14;5:407-18 - PubMed
  22. J Nerv Ment Dis. 2013 Jul;201(7):553-9 - PubMed
  23. Neuropsychiatr Dis Treat. 2014 Aug 25;10:1577-84 - PubMed
  24. Ann Gen Psychiatry. 2012 Jul 02;11(1):18 - PubMed
  25. Pharmacoeconomics. 1996;10 Suppl 2:110-23 - PubMed
  26. Am J Psychiatry. 2011 Jun;168(6):603-9 - PubMed
  27. Ther Adv Psychopharmacol. 2013 Aug;3(4):200-18 - PubMed
  28. Int Clin Psychopharmacol. 2007 Sep;22(5):275-82 - PubMed
  29. J Med Econ. 2015 Mar;18(3):219-29 - PubMed
  30. Int J Soc Psychiatry. 2013 Dec;59(8):771-81 - PubMed
  31. Lancet. 2009 Jan 3;373(9657):31-41 - PubMed
  32. Br J Psychiatry. 2003 Jul;183:50-6 - PubMed
  33. Schizophr Res. 2012 Feb;134(2-3):187-94 - PubMed
  34. J Psychiatr Res. 2013 Feb;47(2):149-54 - PubMed
  35. Lancet. 2009 Aug 22;374(9690):635-45 - PubMed
  36. Br J Psychiatry Suppl. 2009 Nov;52:S43-50 - PubMed
  37. J Med Econ. 2012;15(5):844-61 - PubMed
  38. Int J Psychiatry Clin Pract. 2010 Mar;14(1):53-62 - PubMed
  39. Acta Neuropsychiatr. 2013 Apr;25(2):85-94 - PubMed
  40. J Clin Psychiatry. 2015 Mar;76(3):253-62 - PubMed

Publication Types